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Abstract
Background: The U2 small nuclear ribonucleoprotein particle (snRNP) component SF3b1/
SAP155 is the only spliceosomal protein known to be phosphorylated concomitant with splicing
catalysis. DYRK1A is a nuclear protein kinase that has been localized to the splicing factor
compartment. Here we describe the identification of DYRK1A as a protein kinase that
phosphorylates SF3b1 in vitro and in cultivated cells.
Results: Overexpression of DYRK1A caused a markedly increased phosphorylation of SF3b1 in
COS-7 cells as assessed by Western blotting with an antibody specific for phosphorylated Thr-Pro
dipeptide motifs. Phosphopeptide mapping of metabolically labelled SF3b1 showed that the majority
of the in vivo-phosphopeptides corresponded to sites also phosphorylated by DYRK1A in vitro.
Phosphorylation with cyclin E/CDK2, a kinase previously reported to phosphorylate SF3b1,
generated a completely different pattern of phosphopeptides. By mass spectrometry and
mutational analysis of SF3b1, Thr434 was identified as the major phosphorylation site for DYRK1A.
Overexpression of DYRK1A or the related kinase, DYRK1B, resulted in an enhanced
phosphorylation of Thr434 in endogenous SF3b1 in COS-7 cells. Downregulation of DYRK1A in
HEK293 cells or in HepG2 cells by RNA interference reduced the phosphorylation of Thr434 in
SF3b1.
Conclusion: The present data show that the splicing factor SF3b1 is a substrate of the protein
kinase DYRK1A and suggest that DYRK1A may be involved in the regulation of pre mRNA-splicing.
Background
The excision of introns from pre-mRNA is catalysed by the
spliceosome, a macromolecular machine consisting of
five small nuclear ribonucleoprotein particles (snRNPs)
and a large number of non-snRNP proteins [1]. Spliceo-
some assembly proceeds via the step-wise recruitment of
U1 snRNP, U2 snRNP, and U4/U6·U5 tri-snRNP on a
pre-mRNA as well as multiple rearrangements between
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the spliceosome dissociates into its snRNP subunits,
which take part in ensuing rounds of splicing.
Both spliceosome assembly and splicing catalysis is regu-
lated by reversible protein phosphorylation [1-3]. The
best studied targets for phosphorylation are members of
the SR family of splicing factors, which contain domains
rich in Arg/Ser dipeptides [4]. Several kinases phosphor-
ylate these RS domains and modulate interaction of SR
proteins with other proteins during spliceosome assembly
[5]. In addition, phosphorylation affects the intranuclear
distribution of splicing factors and alternative splice site
selection [6-10].
The only non-SR component of the spliceosome known
to be phosphorylated during splicing catalysis is SF3b1
(also called SAP155 or SF3b155), one of the subunits of
the U2 snRNP-associated complex SF3b [3,11]. SF3b1 is
positioned at the spliceosome catalytic center and con-
tacts pre-mRNA on both sides of the branch site [12].
Phosphorylation of SF3b1 appears to be functionally
important in the basic splicing reaction as it is detected
only in functional spliceosomes and occurs concomitant
with splicing catalysis [3]. The N-terminal part of SF3b1
contains abundant Thr-Pro dipeptides motifs which are
potential phosphorylation sites of proline-directed
kinases like the cyclin-dependent kinases (CDK). Indeed,
cyclin E/CDK2 has been shown to phosphorylate SF3b1 in
vitro and to be associated with the U2 snRNP complex in
vivo [11].
We have recently identified several splicing factors,
including SF3b1, as substrates of the protein kinase
DYRK1A [13]. DYRK1A is a nuclear protein kinase that
has been localised to the splicing factor compartment
[14]. Furthermore, we have previously characterised
DYRK1A as a kinase that targets serine/threonine followed
by a proline residue [15].
Here we report that DYRK1A efficiently phosphorylates
SF3b1 within the TP-rich domain at several sites that are
also phosphorylated by endogenous kinases in COS-7
cells. One of these sites, Thr434, was identified as the res-
idue predominantly phosphorylated by DYRK1A in vitro
and as a major phosphorylation site of SF3b1 in vivo.
Results
SF3b1 is a high affinity in vitro substrate of DYRK1A
We have recently identified SF3b1 as an in vitro substrate
of DYRK1A by screening of a cDNA expression library
from human fetal brain [13]. In order to further character-
ise SF3b1 as a substrate of DYRK1A, we performed a
kinetic analysis of the phosphorylation of His6-SF3b1304–
493, the fusion protein produced from the library clone, by
GST-DYRK1A-∆C. The C-terminally deleted mutant of
GST-DYRK1A was used for in vitro-kinase assays since this
construct exhibits the same substrate specificity but is
more active than wild type GST-DYRK1A [15,16]. The Km
value obtained for total phosphate incorporation into the
substrate was 2.16 +/- 1.72 µM (mean of three independ-
ent experiments +/- S.E.M.), characterising SF3b1 as a
high affinity substrate of DYRK1A. A representative exper-
iment is shown below in Fig. 1A. Notably, His6-SF3b1304–
493 contains 14 Thr-Pro dipeptide motifs (Fig. 1B) which
are potential target sites for DYRK1A.
Phosphorylation of SF3b1 by DYRK1A in COS-7 cells
In order to assess whether DYRK1A phosphorylates SF3b1
in vivo we co-transfected COS-7 cells with expression plas-
mids for GFP-SF3b1-NT and GFP-DYRK1A. Assuming
that DYRK1A may phosphorylate one ore more of the Thr-
Pro dipeptides, we took advantage of a commercially
available antibody which recognises phosphothreonine
C-terminally flanked by proline (pTP) to detect phospho-
rylation of SF3b1. This antibody detected two bands in
the immunoprecipitates from cells overexpressing GFP-
DYRK1A phosphorylates SF3b1 within the TP-domainFigure 1
DYRK1A phosphorylates SF3b1 within the TP-
domain. A, Phosphorylation of His6-SF3b1304–493 by 
DYRK1A. – Data from a representative experiment were 
evaluated by linear regression analysis of the Lineweaver-
Burke plot. B, Schematic representation of human SF3b1 and 
the recombinant fusion proteins used in this study. The car-
boxyterminal part of SF3b1 consists of 22 nonidentical 
repeats related to the regulatory subunit A of protein phos-
phatase 2A (PP2A-like) [3]. Numbers indicate amino acids. 
TP-rich, region rich in Thr-Pro dipeptides; His, hexahistidine 
tag.Page 2 of 13
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weight of about 95 kD) also reacted with the GFP-specific
antibody (Fig. 2A). The difference from the calculated
molecular weight (82.4 kD) is possibly due to post-trans-
lational modifications. As shown in Fig. 2C, both bands
were eliminated by treatment with alkaline phosphatase.
Furthermore, the upper band was also found after immu-
noprecipitation with an SF3b1-specific antibody, but not
in untransfected cells (Fig. 2D). Thus, this band most
likely represents a highly phosphorylated form of GFP-
SF3b1-NT which is present in too low amounts to be
detected by the GFP-specific antibody (see also below, Fig.
7B). Co-transfection of DYRK1A caused a very pro-
nounced and dose-dependent increase in the phosphor-
Phosphorylation of SF3b1 by DYRK1A in COS-7 cellsFigure 2
Phosphorylation of SF3b1 by DYRK1A in COS-7 cells. COS-7 cells were transiently transfected with expression plas-
mids for GFP-SF3b1-NT and the protein kinases DYRK1A or CLK3. Two days after transfection, cells were lysed under dena-
turing conditions and the recombinant proteins were immunoprecipitated with polyclonal GFP antiserum (A, B, C) or 
monoclonal SF3b1 antibody (D). Immunoprecipitates were subjected to Western blot analysis with antibodies specific for 
phosphoThr-Pro (anti pTP), GFP, or SF3b1. A, COS-7 cells were transfected with 1 µg of pEGFP-SF3b1-NT and increasing 
amounts of pEGFP-DYRK1A (0 µg, 0.2 µg, 1 µg and 2 µg of DNA per 6-cm plate). B, Cells were transfected with pEGFP-
SF3b1-NT and either pEGFP-DYRK1A-K188R, pEGFP-DYRK1A (WT), pEGFP (Co), or pEGFP-CLK3. C, Cells were trans-
fected pEGFP-SF3b1-NT and either pEGFP-DYRK1A (DIA) or pEGFP (Co). Cells from one plate were lysed in buffer lacking 
phosphatase inhibitors, and the lysate was incubated for 1 h at 37°C with 2000 u of calf intestinal phosphatase (CIP) before 
immunoprecipitation. D, Cells were transfected pEGFP-SF3b1-NT (left lane) or were not transfected. Migration of the immu-
noprecipitating antibody is indicated (IgG). The asterisk marks a slowly migrating form of SF3b1-NT (see text).Page 3 of 13
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suggesting that DYRK1A phosphorylates SF3b1 in COS-7
cells. This effect required low amounts of GFP-DYRK1A
compared with its substrate GFP-SF3b1-NT, as evidenced
by the direct comparison of GFP-immunoreactivity (sec-
ond lane in Fig. 2A).
To test the specificity of this reaction, we compared the
effects of GFP-CLK3 and GFP-DYRK1A on the phosphor-
ylation of SF3b1-NT. Protein kinases of the CLK family are
related with the DYRK family and also phosphorylate
splicing factors [17]. As a further control, we used GFP-
DYRK1A-K188R which carries a point mutation in the
ATP binding site and exhibits greatly reduced catalytic
activity (1–3% of residual activity [16,18]). As shown in
Fig. 2B, co-expression of GFP-CLK3 failed to induce phos-
phorylation of SF3b1 as compared to GFP alone. As
shown by immunodetection with the GFP-specific anti-
body, GFP-CLK3 was expressed at similar levels as wild
type GFP-DYRK1A (see also Fig. 7B). Immunocomplex
kinase assays with myelin basic protein as substrate con-
firmed that GFP-CLK3 was an active protein kinase when
expressed in COS-7 cells (data not shown). Unexpectedly,
co-expression of DYRK1A-K188R significantly enhanced
phosphorylation of SF3b1-NT, although the effect was
much weaker than that of the wild type kinase (note also
that in the experiment shown DYRK1A-K188R was
expressed at a higher level than wild type DYRK1A). The
result that a mutant of DYRK1A with reduced activity
(K188R), but not the related kinase CLK3, enhanced thre-
onine phosphorylation of SF3b1-NT is evidence of the
specificity of this reaction.
Comparison of the phosphorylation of SF3b1 by DYRK1A 
and cyclin E/CDK2
SF3b1 is phosphorylated concomitant with or just after
catalytic step one of the splicing reaction [3]. The kinase
responsible for this phosphorylation during splicing
catalysis has not been characterised to date, but Seghezzi
et al. [11] have identified SF3b1 as a potential target of
cyclin E/CDK2 complexes. In order to compare the phos-
phorylation of SF3b1-NT-His6 by DYRK1A and cyclin E/
CDK2, we performed a preliminary kinetic analysis of
both reactions by measuring the velocities of phosphate
incorporation at two different substrate concentrations
(0.7 and 7 µM). The approximate Km values calculated
from the results shown in Fig. 3 are very similar for both
kinases (2.75 µM for DYRK1A and 3.51 µM for cyclin E/
CDK2) and indicate that both kinases have a high affinity
for SF3b1.
To answer the question whether both kinases target the
same phosphorylation site(s) in SF3b1, we generated
phosphopeptide fingerprints. SF3b1-NT-His6 was phos-
phorylated by either GST-DYRK1A-∆C or cyclin E/CDK2
in vitro, and tryptic peptides of SF3b1-NT were analysed by
two-dimensional peptide mapping. The pattern of phos-
phopeptides derived from DYRK1A-labelled SF3b1 (Fig.
4A) differed completely from the pattern obtained by cyc-
lin E/CDK2 (Fig. 4B), and mixing of the peptides from
both experiments revealed no detectable comigration of
phosphopeptides (A+B). This result indicates that both
kinases phosphorylate different sites in SF3b1.
DYRK1A phosphorylates SF3b1 in vitro on physiologically 
relevant sites
Next we asked whether the phosphorylation pattern of
SF3b1 in vivo better matches the in vitro-pattern obtained
with DYRK1A or with cyclin E/CDK2. COS-7 cells were
transfected with pEGFP-SF3b1-NT and metabolically
labelled by incubation with 32P-orthophosphate. Phos-
phopeptide mapping of the immunoprecipitated GFP-
SF3b1-NT fusion protein showed that the in vivo-phos-
phorylation pattern (Fig. 4C) strikingly resembled the
phosphorylation pattern obtained by in vitro-phosphor-
ylation with DYRK1A (Fig. 4A). Six of the spots on the in
vivo-map matched phosphopeptides generated by
DYRK1A in vitro and comigrated in the map of a mixed
sample (Fig. 4A+C), strongly suggesting that the phos-
phopeptides generated in vitro by DYRK1A are identical
with those generated in vivo. Unlike in vitro, however, spot
1 was much more intense than spot 2. A possible explana-
tion for this difference is a superposition of signals
derived from spot 1 and a comigrating phosphopeptide
(spot X) that is phosphorylated in vivo by a kinase other
than DYRK1A (see below, Fig. 5B). No match was detect-
able between the cyclin E/CDK2 phosphopeptide map
and the in vivo map (Fig. 4B+C). This result provides evi-
dence that the major part of the phosphorylation within
the Thr-Pro-rich domain of SF3b1 is catalysed by DYRK1A
or a related kinase with similar substrate specificity. How-
ever, it cannot be excluded that relevant CDK2 sites
escaped detection because phosphopeptides were lost
during purification or were poorly soluble in the running
buffers.
Identification of SF3b1 phosphorylation sites
His6-SF3b1304–493 was phosphorylated with GST-DYRK1A
in vitro and tryptic peptides were analysed for phosphor-
ylation by tandem mass spectrometry (MS2). Two phos-
phorylated peptides were identified: (1)
VLPPPAGYVPIRTPAR, containing Thr426 (underlined) as
the phosphoamino acid; the phosphorylated residue
completely inhibited tryptic cleavage at the preceding Arg
whereas in an unphosphorylated sample, this cleavage
occurred freely. (2) KLTATPTPLGGMTGFHMQTEDR
(with both Met residues in the sulphoxide form – a side
reaction of preparation). MS2 and MS3 analysis of this
peptide indicated that the phosphorylation was confined
to either of the first two threonines of the peptide (Thr432Page 4 of 13
(page number not for citation purposes)
BMC Biochemistry 2006, 7:7 http://www.biomedcentral.com/1471-2091/7/7or Thr434) but from the data the labelled residue could
not be distinguished. This was because the predicted frag-
ment ions needed to resolve this question laid beyond the
dynamic range of the ion-trap instrument. Attempts to
examine smaller MS2 ions further by MS3 to gain access to
this region were unproductive, as were secondary digest
attempts with chymotrypsin. We considered Thr434 the
more likely target because DYRK1A is a proline-directed
kinase. Therefore we prepared alanine mutants of Thr426
and Thr434 by site directed mutagenesis of SF3b1-NT. In
addition, Thr273 and Thr303 were mutated because the
surrounding sequences of both threonines (Thr273:
GRGDT273P; Thr303: TERDT303P) matched known target
sequences of DYRK1A (RXXS/TP[15]; RXS/TP[19]).
The mutant proteins were phosphorylated with GST-
DYRK1A-∆C in vitro and analysed by peptide mapping.
Mutation of Thr434 resulted in the loss of the two most
prominent spots (spots 1 and 2; right panels of Fig 5A),
indicating that Thr434 is the major phosphorylation site
for DYRK1A. The existence of two different phosphopep-
tides containing Thr434 can be explained by incomplete
tryptic cleavage as the MS analysis showed this peptide to
exist with and without the lysine at the N-terminus. Such
ragged N- or C-termini can be expected when an XRKX
sequence is cleaved by trypsin. The absence of one spot in
the phosphopeptide map of the T273A mutant identified
Thr273 as one of the minor in-vitro phosphorylation sites
of DYRK1A (Fig. 5A, arrow in the left panel). The mutants
T426A and T303A yielded the same pattern of spots as the
wild type protein (data not shown). The failure to detect
the VLPPPAGYVPIRTPAR phosphopeptide containing
Thr426, which was identified as a phosphorylated residue
by MS, may be due to poor solubility of this peptide under
the conditions applied.
Next we asked whether Thr273 and Thr434 are in vivo
phosphorylation sites of SF3b1. The respective point
mutants of GFP-SF3b1-NT were metabolically labelled in
COS-7 cells and subjected to phosphopeptide mapping.
Analysis of SF3b1-NT-T273A did not reveal differences
between the wild type and the mutated protein (data not
shown). In contrast, one of the major phosphopeptides
(spot 2) was absent in the map of GFP-SF3b1-NT-T434A
as compared to the wild type protein (Fig. 5B). This result
confirms our conclusion that spot 2 represents the same
phosphopeptide in the in vitro and the in vivo-maps (Fig.
4). We assume that the absence of the other peptide (spot
1) is masked by a comigrating phosphopeptide (spot X).
Spot X is lacking in SF3b1-NT-T434A after phosphoryla-
tion by DYRK1A in vitro, hence this phosphopeptide
appears to harbour the only major phosphorylation site
not recognised by DYRK1A. These data indicate that
Thr434 in SF3b1 is phosphorylated by endogenous
kinases in COS-7 cells.
Overexpression of DYRK1A increases phosphorylation of 
SF3b1 at in vivo-phosphorylation sites
As shown in Fig. 2A, overexpression of DYRK1A increases
the phosphorylation of SF3b1 in COS-7 cells. To investi-
gate whether DYRK1A targets the same sites that are
already phosphorylated in vivo, we compared the phos-
Kinetic analysis of SF3b1 phosphorylation by DYRK1A and CDK2F gure 3
Kinetic analysis of SF3b1 phosphorylation by DYRK1A and CDK2. SF3b1-NT-His6 was phosphorylated with GST-
DYRK1A-∆C or cyclin E/CDK2 at two different substrate concentrations (0.7 and 7 µM). Phosphate incorporation was meas-
ured at different time points (2, 4 and 8 minutes). The slope of the straight line reflects the velocity of phosphorylation at the 
different substrate concentrations. The calculated Km values are indicated. The experiment was repeated with similar results.Page 5 of 13
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endogenous kinases in COS-7 cells with the phosphopep-
tides obtained after cotransfection of GFP-DYRK1A. As
shown in Fig. 6, intensities of at least five peptides (spots
2–6) increased upon coexpression of GFP-DYRK1A rela-
tive to spot X/1. It should be noted that the comparison
with spot X/1, which includes the DYRK1A-phosphor-
ylated spot 1, underestimates the degree of the increase
caused by cotransfection of DYRK1A. In addition, three
new spots appeared that were not detectable when SF3b1
was labelled without coexpression of DYRK1A (arrows).
This result demonstrates that DYRK1A can phosphorylate
other residues in addition to Thr434 that are endogenous
phosphorylation sites.
Phosphorylation of Thr434 in endogenous SF3b1
In order to facilitate detection of phosphorylated Thr434,
we raised a polyclonal antiserum against a peptide com-
prising residues 429–439 of SF3b1, phosphorylated at
Thr434. The affinity-purified antibody recognised wild
type SF3b1-NT-His6 after in vitro-phosphorylation by
DYRK1A, but not the unphosphorylated protein or
SF3b1-NT-His6-T434A (Fig. 7A). In contrast, the commer-
cial pThrPro-specific antibody also bound to other phos-
phorylated ThrPro motifs in the T434A mutant of SF3b1.
This result shows that the pT434-directed antibody exhib-
its high specificity for this phosphorylation site in SF3b1.
The anti-pT434 antibody was then used to study the phos-
phorylation of Thr434 in transfected COS-7 cells. To
assess the specificity of the reaction, several nuclear pro-
tein kinases were tested in parallel with DYRK1A for their
capacity to enhance phosphorylation of Thr434 in GFP-
SF3b1-NT. DYRK1B is the kinase most closely related to
DYRK1A (85% of identical amino acids in the catalytic
domain [20]). HIPK2 (homeodomain-interacting protein
kinase 2) was selected as a more distant member of the
DYRK family (42% identity) [21], and CLK3 is a kinase
DYRK1A, but not cyclin E/CDK2 phosphorylates SF3b1 in vitro on phosphopeptides comigrating with the endogenous phos-phopeptides from COS-7 cellsFigure 4
DYRK1A, but not cyclin E/CDK2 phosphorylates SF3b1 in vitro on phosphopeptides comigrating with the 
endogenous phosphopeptides from COS-7 cells. SF3b1-NT-His6 was labelled in vitro by GST-DYRK1A-∆C (A) or cyclin 
E/CDK2 (B). GFP-SF3b1-NT was immunoprecipitated from COS-7 cells after metabolic labelling with 32PO4 (C). Recombinant 
proteins were subjected to two-dimensional phosphopeptide mapping. To verify that spots detected in different experiments 
are identical, samples were mixed and analysed on the same plate (A+B, A+C, B+C). Numbers label those spots that were 
both present in panels A and C. The panels show only the relevant area of the plates.Page 6 of 13
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shown in Fig. 7B, the pThr434-specific antibody detected
SF3b1-NT in cells that did not overexpress DYRK1A (left-
most lane). This result is consistent with the labelling of
spots 1 and 2 by endogenous kinases in COS-7 cells (Fig.
4C, 5B, and 6A). Signal intensity was dose-dependently
enhanced by co-expression of DYRK1A or DYRK1B but
not DYRK1A-K188R. SF3b1-T434A (lane 5) was not rec-
ognised by the antibody, confirming that the antibody
was indeed specific for phosphoThr434. Notably, co-
expression of HIPK2, but not CLK3, also resulted in an
increased phosphorylation of Thr434 in SF3b1-NT. A sec-
ond band (marked by an asterisk in Fig. 7B) could also be
identified as a form of SF3b1-NT because of its absence in
cells transfected with SF3b1-NT-T434A. As noted above
(Fig. 2A), it is likely that this band represents a posttrans-
lationally modified form of the protein.
In addition to the recombinant SF3b1-NT protein, the
anti-pT434 antibody labelled a band with an apparent
molecular mass of 150 kDa that was only detectable in
lysates of cells overexpressing catalytically active DYRK1A
or DYRK1B. This band co-migrated with the endogenous
SF3b1 protein as identified by a commercially available
antibody. As shown in Fig. 7C, the 150-kDa band was also
detected in a nuclear protein fraction purified from
DYRK1A-overexpressing COS-7, further supporting the
identification as SF3b1. These data provide evidence that
DYRK1A and DYRK1B can phosphorylate the full length,
endogenous SF3b1 protein in intact cells. In contrast,
overexpression of HIPK2 did not enhance phosphoryla-
tion of Thr434 in SF3b1, suggesting that this kinase can-
not phosphorylate the endogenous protein in the
spliceosome.
Phosphorylation of SF3b1 by endogenous DYRK1A
In order to assess the role of endogenous DYRK1A in the
phosphorylation of SF3b1, we constructed two plasmids
expressing small hairpin RNA (shRNA) for specific down-
regulation of human DYRK1A. The target sequences were
carefully selected to avoid potential effects on DYRK1B
mRNA. As shown in Fig. 8A, transient transfection of
either one of the shRNA constructs efficiently reduced the
level of GFP-DYRK1A, suggesting that they should also
downregulate endogenous DYRK1A which is expressed at
much lower levels. Next we determined the effect of the
SF3b1 is phosphorylated at Thr434 by endogenous kinases in COS-7 cells and in vitro by DYRK1AFigure 5
SF3b1 is phosphorylated at Thr434 by endogenous kinases in COS-7 cells and in vitro by DYRK1A. A, SF3b1-NT-
His6 (wt) and point mutants of Thr273 (T273A) or Thr434 (T434A) were phosphorylated by GST-DYRK1A-∆C in vitro. B, 
GFP-SF3b1-NT (wt) or the alanine mutant of Thr434 (T434A) were expressed in COS-7 cells, metabolically labelled with 32P 
and purified by immunoprecipitation with a GFP-specific antiserum. Phosphopeptide maps were generated as described above. 
Arrows point to phosphopeptides that are absent in the mutants. X marks a spot apparently superimposing spot1 (see text).Page 7 of 13
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SF3b1-NT in two different human cell lines (Fig. 8B).
Transient transfection of either construct resulted in a
marked reduction of Thr434 phosphorylation, indicating
that DYRK1A is the major Thr434 kinase in HEK193T cells
and in HepG2 cells.
Discussion
The splicing factor Sf3b is an integral part of U2 snRNP
and plays an essential role during spliceosome assembly
and recognition of the intron's branch point. One of the
components of SF3b, SF3b1, is known to be reversibly
phosphorylated during splicing catalysis [3], suggesting
that protein kinases play a role in the regulation of splic-
ing. Previous studies have shown that cyclin E/CDK2
complexes associate with spliceosomal proteins in vivo,
and that CDK2 phosphorylates SF3b1 in vitro [12,22].
Here we provide evidence that the protein kinase DYRK1A
phosphorylates SF3b1 in vitro and in vivo.
The N-terminal part of Sf3b1 harbours a large number of
Thr/Pro dipeptide motifs within a 240-amino acid region
preceding the carboxyterminal repeat domain (Fig. 1).
Both DYRK1A and CDK2 are proline-directed kinases, i.e.
they phosphorylate serine or threonine residues followed
by a proline residue [15,23]. It has been shown that cyclin
E/CDK2 phosphorylates SF3b1 in vitro at multiple sites
within the TP-rich domain [22]. Here we demonstrate that
SF3b1 is phosphorylated by DYRK1A and cyclin E/CDK2
in vitro with similarly high affinity, but at different sites.
Strikingly, the majority of the in vivo-phosphorylation
sites within the N-terminal domain of SF3b1 corre-
sponded to sites phosphorylated by DYRK1A in vitro, and
overexpression of DYRK1A also enhanced the labelling of
these phosphopeptides in vivo. Importantly, overexpres-
sion of DYRK1A resulted in the increased phosphoryla-
tion of Thr434 in endogenous SF3b1, indicating that
enzyme and substrate come into contact in living cells.
However, in contrast to cyclin E/CDK2, DYRK1A does not
appear to be stably associated with SF3b1 as we failed to
detect the interaction in pulldown assays (data not
shown).
Our conclusion that DYRK1A is the major SF3B1 kinase in
asynchronously growing COS-7 cells is not in contradic-
tion to previous reports that CDK2 phosphorylates SF3b1
[11,22] but rather complements these studies. Seghezzi et
al. reported that only about 30% of the SF3b1-phosphor-
ylating activity in immunoprecipitated SF3b1 complexes
was inhibited by the CDK inhibitor p21, leading the
authors to suggest "the existence of other kinases in the
(...) complex" [11]. Boudrez et al. [22] also observed that
SF3b1 kinase activity in lysates from COS-1 cells was only
partially suppressed by the CDK inhibitor roscovitine. It is
well possible that the relative contribution of different
kinases to phosphorylation of SF3b1 varies in different
experimental systems (nuclear extracts, cellular extracts,
immunoprecipitated splicing complexes). In our in vivo-
phosphopeptide maps, no spot corresponded to a site
also phosphorylated by cyclin E/CDK2 in vitro, indicating
that CDK2 did not contribute detectably to phosphate
incorporation into SF3b1 under these conditions. In con-
trast, 6 phosphopeptides matched spots that were
obtained after phosphorylation with DYRK1A in vitro,
indicating that DYRK1A or another protein kinase with
similar substrate specificity, e.g. DYRK1B [15,20], cataly-
ses the phosphorylation of SF3b1 in COS-7 cells at multi-
ple sites. Overexpression of DYRK1B caused indeed an
increase in the phosphorylation of Thr434 in SF3b1.
Other members of the DYRK family, DYRK2 and DYRK3,
are primarily localised in the cytosol [24] and are thus
unlikely to phosphorylate SF3b1. The proposed role of
DYRK1A as a regulator of an essential splicing factor is in
agreement with its ubiquitous expression [24], the evolu-
tionary conservation of DYRK kinases throughout the
eukaryotic kingdoms, and the embryonic lethality of mice
homozygous for a targeted deletion of the Dyrk1a gene
[25]. In contrast, DYRK1B has a more restricted pattern of
expression, and DYRK1B deficient mice are viable (S.
Leder, M. Moser and W. Becker, unpublished data). Fur-
ther studies will be necessary to reveal the roles of
DYRK1A and DYRK1B in splicing.
Our experiments do not formally exclude the possibility
that another nuclear kinase produces the phosphorylation
pattern observed in COS-7 cells. We have tested HIPK2 as
a DYRK-related kinase and found that this kinase was
indeed able to phosphorylate Thr434 in GFP-SF3b1-NT.
However, overexpression of HIPK2 did not cause phos-
Overexpression of DYRK1A increases the phosphorylation of endogenous sites in COS-7 cellsFigure 6
Overexpression of DYRK1A increases the phosphor-
ylation of endogenous sites in COS-7 cells. GFP-SF3b1-
NT was expressed in COS-7 cells either alone (A) or coex-
pressed with GFP-DYRK1A (B) and metabolically labelled 
with 32P. SF3b1 fusion proteins were subjected to phos-
phopeptide mapping as above. Intensities of peptide maps A 
and B were adjusted to spot X/1.Page 8 of 13
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Detection of Thr434 phosphorylation with the help of a phosphorylation site-specific antibodyFigure 7
Detection of Thr434 phosphorylation with the help of a phosphorylation site-specific antibody. A, Verification of 
antibody specificity. – Recombinant SF3b1-NT-His6 (WT) or the T434A point mutant thereof were phosphorylated in vitro by 
GST-DYRK1A-∆C or incubated under the same conditions in the absence of GST-DYRK1A-∆C. The indicated amounts of 
SF3b1-NT-His6 (500 ng, 100 ng, 20 ng, 4 ng) were separated by SDS-PAGE and subjected to Western blot analysis with anti-
bodies specific for pT434, pThrPro (pTP), and SF3b1. B, Phosphorylation of Thr434 in vivo. – COS-7 cells seeded in 6-well 
plates were co-transfected with expression plasmids for wild type GFP-SF3b1-NT (WT) or the T434A mutant (0.6 µg/well) 
and either GFP (Co) or GFP fusion constructs (0.1 µg, 0.2 µg or 0.4 µg/well) of the indicated protein kinases (wild type 
DYRK1A or the K188R point mutant, DYRK1B, CLK3, HIPK2). The total amount of transfected DNA was kept constant by 
addition of vector DNA where appropriate. Two days after transfection, total cellular lysates were prepared and subjected to 
Western blot analysis with antibodies specific for pT434, pThrPro (pTP), SF3b1, or GFP. A shorter exposure of the top panel 
is shown below because the most intense signals exceeded the linear range of the detection camera. A slowly migrating form of 
SF3b1-NT is marked by an asterisk (*). C, Nuclei were purified from COS-7 cells transfected with expression plasmids for wild 
type GFP-DYRK1A (1 µg, 2 µg or 4 µg/6-cm plate) or the point mutant K188R. Nuclear proteins were subjected to Western 
blot analysis with the indicated antibodies.
BMC Biochemistry 2006, 7:7 http://www.biomedcentral.com/1471-2091/7/7phorylation of Thr434 in endogenous SF3b1, making it
unlikely that this kinase targets SF3b1 in vivo. Moreover,
downregulation of DYRK1A by RNA interference led to a
marked reduction of Thr434 phosphorylation in
HEK293T and in HepG2 cells, providing evidence that in
these cell lines DYRK1A is the major kinase that targets
this phosphorylation site. It should be noted that one pre-
dominant in vivo-phosphopeptide (spot X in Fig. 5B) was
neither labelled by DYRK1A nor by CDK2 in vitro, provid-
ing evidence that at least one more kinase phosphorylates
SF3b1.
The present data identify Thr434 as the major phosphor-
ylation site of DYRK1A in SF3b1. This site does not exactly
match the consensus recognition site for DYRK1A as pre-
viously determined in peptide assays [15,26] since no
arginine is present at position -2 or -3 relative to the phos-
phorylation site. However, in vitro-assays with a peptide
mimicking the sequence context of Thr434 showed that
this target sequence is similarly well recognised as a pep-
tide designed according to the consensus phosphoryla-
tion sequence for DYRK1A (K. de Graaf, R. Frank and W.
Becker, unpublished data).
At present we can only speculate on the effects of the
phosphorylation of SF3b1. Protein-protein interactions of
SF3b1 with U2AF35/65, the SF3b component p14, and
nuclear inhibitor of protein phosphatase 1 (NIPP1) have
been mapped to the TP-rich domain [12,22,27]. NIPP1
contains a phosphothreonine-binding forkhead-associ-
ated (FHA) domain, and the binding to NIPP1 has been
shown to depend on the phosphorylation of SF3b1 by
cyclin/CDK complexes [22]. Coexpression of DYRK1A
failed to alter the binding of SF3b1-NT to NIPP1 in pull-
down assays (data not shown), most likely because CDKs
and DYRK1A phosphorylate different sites within SF3b1.
It should also be noted that Thr434 is located at the C-ter-
minal end of the TP-rich domain and was absent in some
of the constructs to which protein interactions had been
mapped in the studies mentioned above. The location of
Thr434 in the hinge region between the TP-rich domain
and the C-terminal domain makes it tempting to specu-
late that phosphorylation of this residue may regulate the
conformational changes of SF3b that have been proposed
to be required for binding of the RNA [28].
Conclusion
The present data indicate that DYRK1A and/or DYRK1B
phosphorylate specific threonine residues within the TP-
rich domain of the spliceosomal protein SF3b1. Phospho-
rylation of SF3b1 has previously been shown to be
increased during splicing catalysis [3] and in mitosis [22].
Further work will be necessary to reveal the role of DYRK-
related kinases under these conditions and which effects
they may have on the function of the spliceosome.
Methods
Antibodies
The following antibodies were commercially obtained:
rabbit polyclonal antibody for GFP (Molecular Probes,
Eugene, USA) and monoclonal antibodies for GFP and
SF3b1/SAP155 (MBL, Nagoya, Japan) and phosphothreo-
nine-proline (p-Thr-Pro-101; Cell Signaling Technology,
Beverly, MA, USA). The p-Thr-Pro-101 antibody reacts
with proteins phosphorylated on the Thr-Pro motif in an
otherwise highly context-independent fashion (character-
isation by the supplier). Horseradish peroxidase-coupled
secondary antibodies were purchased from Perbio Sci-
ence, Bonn, Germany (anti rabbit IgG, anti mouse IgG/
IgM) and Amersham Bioscience (anti mouse IgG). A rab-
Downregulation of endogenous DYRK1A reduces phosphor-ylation of Thr434 in SF3b1Figure 8
Downregulation of endogenous DYRK1A reduces 
phosphorylation of Thr434 in SF3b1. A, Test of shRNA 
vectors for DYRK1A knockdown. – HEK293T cells seeded in 
6-well plates were co-transfected with expression plasmids 
for GFP-DYRK1A (0.2 µg/well) and either empty vector 
(Ctrl) or plasmids expressing to different small hairpin RNAs 
directed against DYRK1A (673 or 2060; 0.8 µg DNA/well). 
Two days after transfection, nuclear extracts were prepared 
and subjected to Western blot analysis with a DYRK1A-spe-
cific antibody. B, Effect of DYRK1A knockdown on Thr434 
phosphorylation. – HEK293T cells or HepG2 cells were co-
transfected with the expression plasmid for GFP-SF3b1-NT 
(0.5 µg/well) and the pSUPER constructs (0.8 µg/well). Total 
cellular lysates were subjected to Western blot analysis with 
antibodies specific for pThr434 or GFP. The asterisks mark 
unspecific bands (*).Page 10 of 13
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ylated at Thr434 was raised against the peptide
RKLTApTPTPLG (where pT indicates phosphothreonine).
The antiserum was purified by affinity chromatography
on CNBr-activated Sepharose to which the phosphopep-
tide antigen had been attached covalently and passed
down a CNBr-Sepharose column to which the corre-
sponding unphosphorylated peptide had been coupled
(custom immunisation and antibody purification by Bio-
Genes, Berlin, Germany). The purified antibody was used
for immunodetection on Western blots at a dilution of
1:200 (0.5 µg/ml).
Expression plasmids and isolation of recombinant proteins
The plasmids for bacterial expression of GST-DYRK1A-∆C
and GST-DYRK1A-cat and the mammalian expression
clones for GFP-DYRK1A, GFP-DYRK1A-K188R, GFP-
DYRK1B-p69 and GFP-CLK3 have been described earlier
[13,18,20,24]. The plasmid encoding GFP-HIPK2 was
kindly provided by M.L. Schmitz (Bern, Switzerland) [29].
An expression plasmid for a His6-tagged fragment of
SF3b1 (pQE-SF3b1304–493, encoding amino acids 304 to
493; numbering according to O75533 was previously iso-
lated from a human fetal brain expression library in a
screen for substrates of DYRK1A [13]. A construct
(pET28a-SF3b1-NT) coding for amino acids 1 to 511 of
human SF3b1 fused to a C-terminal His6-tag was gener-
ated by PCR cloning (vector pET28a, Novagen, Madison,
WI, USA). pEGFP-SF3b1-NT expresses the amino acids 1
to 492 of human SF3b1 in the pEGFP-C1 vector system
(Clontech, Palo Alto, CA, USA). Catalytically active
human cyclin E/CDK2 complexes E were expressed in
insect cells and purified as described [30].
GST- and His6-tagged fusion proteins were expressed in E.
coli and affinity purified using glutathione S-Sepharose 4B
(Amersham Bioscience) or nickel-charged nitrilotriacetic
acid agarose beads (Qiagen, Hilden, Germany). Proteins
were eluted under native conditions (reduced glutathione
or imidazol). His6-tagged proteins were purified by gel fil-
tration through a Sephadex G25 column (NAP™-5 col-
umn, Amersham Bioscience) and equilibrated in 10 mM
Tris pH 7.4, 100 mM NaCl. Point mutants of pET28a-
SF3b1-NT were produced with the help of QuikChange™
Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA)
and verified by sequencing. Point mutants of pEGFP-
SF3b1-NT were made by subcloning of the mutated
cDNAs into pEGFP-SF3b1-NT.
RNA interference
pSuper vectors [31] were constructed that direct the syn-
thesis of small interfering RNA specific for two different
19-bp target sequences within the human DYRK1A mRNA
(bp673–691, GCACAGATAGAAGTGCGAC and bp 2060–
2079, CGACTTCTTCCTCGACATC, numbering refers to
EMBL:U52373).
Kinetic analysis of SF3b1 phosphorylation
The Km value of the phosphorylation of His6-SF3b1304–493
by GST-DYRK1A-∆C was determined as detailed previ-
ously [15]. Apparent Km values of three independent
experiments each done at five different substrate concen-
trations were derived by (nonlinear) fitting of the data
into the Michaelis-Menten equation with the help of the
GraphPad Prism 1.03 program (GraphPad Software, San
Diego, CA, USA). R2 values for the non-linear fitting were
always greater than 0.9. Only for the graphical representa-
tion in Fig. 1A data were evaluated by linear regression.
For a comparative kinetic analysis, SF3b1-NT-His6 was
phosphorylated by either GST-DYRK1A-∆C (1 unit/ml) or
cyclin E/CDK2 (400 units/ml) in the presence of 50 µM
ATP (66.6 µCi/ml) and phosphate incorporation was
measured at the time points indicated in Fig. 3. The veloc-
ities (v1 and v2) of phosphate incorporation by both
kinases were determined at substrate concentrations of S1
= 0.7 µM and S2 = 7 µM, and approximate Km values were
calculated using the transformed Michaelis-Menten equa-
tion Km = (v2 – v1)/((v1/[S1]) – (v2/[S2])). One unit of
DYRK1A is that amount which catalysed the phosphoryla-
tion of 1 nmol of the synthetic peptide DYRKtide (at 100
µM) in 1 min at 30°C [13]. One unit of cyclin E/CDK2 is
the amount of catalytically active kinase complex that
incorporates 1 pmol phosphate in 5 µg histone H1 in 30
min at 30 °C in CDK2 kinase buffer (50 mM HEPES pH
7.5, 10 mM MgCl2, 1 mM sodium vanadate, 10 mM NaF).
Cell culture, cell lysates, immunoprecipitations and 
immunoblotting
HEK293T and COS-7 cells were grown in Dulbecco's
modified Eagle's medium (DMEM) high glucose, supple-
mented with 10 % fetal calf serum (FCS). Phosphate-free
DMEM was obtained from Sigma-Aldrich (catalogue
number D3656) and supplemented with 3.7 g/l NaHCO3,
0.11 g/l sodium pyruvate and 10 % dialyzed phosphate
free FCS (Sigma-Aldrich, catalogue number F0392). The
cells were transfected using FuGENE (Roche, Mannheim,
Germany) as suggested by the manufacturer. For the
detection of phosphorylated proteins, cell lysis and
immunoprecipitation were done under denaturing condi-
tions as described earlier [13]. For analysis of nuclear pro-
teins (Figs. 7C and 8A), cells on a 6-cm plate were lysed by
incubation in 1 ml of 20 mM Hepes pH 7.4, 150 mM
NaCl, 1.5 mM MgCl2, 0.02% NP40 for 10 min on ice.
Nuclei were collected by low speed centrifugation (1.300
× g, 1 min), washed in the lysis buffer, and nuclear pro-
teins were prepared for gel electrophoresis by incubation
in SDS sample buffer at 96°C.Page 11 of 13
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Proteins were separated by SDS gel electrophoresis and
stained with Coomassie Blue. Cut bands were digested
with trypsin and the resulting peptides analysed by elec-
trospray mass spectrometry on a ThermoFinnigan LCQ
Classic ion-trap instrument using static nanospray deliv-
ery, as previously described [16]. Additional MALDI anal-
yses were performed on a Waters TofSpec 2E instrument
using alpha-cyano-4-hydroxycinammic acid matrix.
Two-dimensional phosphopeptide mapping
About 4 µg of SF3b1-NT-His6 or its mutant versions were
phosphorylated in vitro by GST-DYRK1A-∆C (1.5 units/
ml) or CDK2/cyclin E (500 units/ml) in the respective
kinase buffers supplemented with 10 µM [γ-32P]ATP (100
µCi/ml) and 100 mM NaCl. For metabolic labelling of
GFP-SF3b1-NT, transfected COS-7 cells (in 6 cm-diameter
plates) were incubated with 200–400 µCi/plate of carrier-
free H3 32PO4 (Hartmann Analytic GmbH, Braunschweig,
Germany) as described previously [13]. After incubation
for 2.5 h, SDS lysates were prepared and the GFP-tagged
proteins were immunoprecipitated with the help of a pol-
yclonal anti-GFP antiserum [13]. The in vitro-phosphor-
ylated SF3b1 and the immunoprecipitates containing in
vivo-phosphorylated SF3b1 were purified by SDS-PAGE.
The labelled proteins were recovered from cut gel slices,
digested with trypsin and subjected to two-dimensional
phosphopeptide mapping as detailed previously [32].
Thin-layer electrophoresis on cellulose plates (first
dimension) and subsequent thin-layer chromatography
were run in acidic pH-1.9 buffer (2.2% formic acid/7.75%
acetic acid).
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